Clinical Trials
10 trialsNCT05580562 2026-04-16
ACTION
Jazz Pharmaceuticals
Phase 3 Recruiting
NCT04617002 2025-08-20
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
Jazz Pharmaceuticals
Approved for marketing
NCT03295396 2025-07-28
ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
Jazz Pharmaceuticals
Phase 2 Terminated
NCT03416530 2025-02-14
ONC201 in Pediatric H3 K27M Gliomas
Jazz Pharmaceuticals
Phase 1 Terminated
NCT02525692 2024-12-24
Oral ONC201 in Adult Recurrent Glioblastoma
Jazz Pharmaceuticals
Phase 2 Terminated
NCT03485729 2024-12-24
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
Jazz Pharmaceuticals
Phase 2 Terminated
NCT02863991 2024-07-03
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
Jazz Pharmaceuticals
Phase 1/2 Terminated
NCT05392374 2022-05-26
Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas
Jazz Pharmaceuticals
No longer available
NCT03134131 2022-03-14
Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas
Jazz Pharmaceuticals
No longer available
NCT02038699 2021-04-30
A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer
Jazz Pharmaceuticals
Phase 1/2 Withdrawn